CWAM
CLDX icon

Columbia Wanger Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Columbia Wanger Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$30.6M Buy
718,141
+371,630
+107% +$15.9M 0.46% 100
2017
Q3 		$14.9M Sell
346,511
-221,930
-39% -$8.32M 0.22% 152
2017
Q2 		$21.1M Buy
568,441
+167,135
+42% +$7.39M 0.3% 136
2017
Q1 		$21.7M Sell
401,306
-11,751
-3% -$612K 0.31% 140
2016
Q4 		$21.9M Buy
413,057
+219,222
+113% +$12.5M 0.31% 141
2016
Q3 		$11.7M Sell
193,835
-156,961
-45% -$9.77M 0.15% 174
2016
Q2 		$23.1M Buy
350,796
+152,369
+77% +$9.67M 0.27% 139
2016
Q1 		$11.3M Sell
198,427
-42,240
-18% -$4.75M 0.12% 169
2015
Q4 		$56.6M Buy
240,667
+33,359
+16% +$7.27M 0.57% 67
2015
Q3 		$32.8M Buy
207,308
+34,528
+20% +$9.77M 0.26% 138
2015
Q2 		$65.4M Sell
172,780
-13,933
-7% -$5.53M 0.42% 91
2015
Q1 		$78.1M Sell
186,713
-26,400
-12% -$9.44M 0.42% 87
2014
Q4 		$58.3M Sell
213,113
-24,994
-10% -$6.21M 0.29% 115
2014
Q3 		$46.3M Sell
238,107
-800
-0.3% -$174K 0.21% 157
2014
Q2 		$58.5M Buy
238,907
+60,774
+34% +$13.7M 0.23% 145
2014
Q1 		$47.2M Buy
178,133
+66,733
+60% +$25.6M 0.19% 179
2013
Q4 		$40.5M Buy
+111,400
New +$42.9M 0.15% 199

Other funds holding CLDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Columbia Wanger Asset Management's CLDX Position: Q4 2017 in Review

Columbia Wanger Asset Management increased its Celldex Therapeutics (CLDX) stake by 107% in Q4 2017, buying an estimated $15.9M and bringing the position to 718,141 shares worth $30.6M. The position accounts for 0.46% of the portfolio, ranked #100.

Columbia Wanger Asset Management first reported a position in CLDX in Q4 2013 and has held it in 17 quarters since. The position peaked at $78.1M in Q1 2015. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • Columbia Wanger Asset Management held 718,141 shares of Celldex Therapeutics worth $30.6M as of Q4 2017.
  • Columbia Wanger Asset Management bought 371,630 Celldex Therapeutics shares in Q4 2017, an estimated $15.9M.
  • Celldex Therapeutics made up 0.46% of Columbia Wanger Asset Management's portfolio in Q4 2017, its #100 holding.
  • Columbia Wanger Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 17 quarters since.
  • Columbia Wanger Asset Management's Celldex Therapeutics position peaked at $78.1M in Q1 2015.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on Columbia Wanger Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.